Why the study?
Does the presence of a pathogenic sarcomere mutation increase heart failure events in patients with hypertrophic cardiomyopathy?
Does the presence of a pathogenic sarcomere mutation increase heart failure events in patients with hypertrophic cardiomyopathy?
Answers are grounded in this paper and cite their sources.
In patients with hypertrophic cardiomyopathy, the presence of any disease-causing sarcomere mutation is a clinically relevant predictor of increased heart failure events, regardless of the specific mutation type.
The presence of a pathogenic sarcomere mutation in patients with hypertrophic cardiomyopathy was associated with an increase in heart failure events, with no differences in event rates seen between myosin heavy chain and myosin-binding protein C genotype-positive patients. The presence of a disease-causing mutation seems more clinically relevant than the specific mutation itself.
No takes yet. Share an insight, caveat, or question.
Li et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: